New diagnostic division will acquire, invest in, and develop a portfolio of diagnostic solutions for the screening, diagnosis, and management of lung cancer.

新的诊断部门将收购、投资和开发肺癌筛查、诊断和管理的诊断解决方案组合。

MENLO PARK, Calif., March 29, 2024 /PRNewswire/ -- Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount.

加利福尼亚州门洛帕克，2024年3月29日/PRNewswire/--由Ajax Health，KKR和Hologic，Inc.建立的专用肺癌平台Maverix Medical今天宣布以未披露的金额收购Cirrus Bio。

Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role in clinical outcomes. The founders of Cirrus Bio, David Mallery (CEO) and Scott Morris (CSO), have previously founded and led the Molecular Profiling Institute (acquired by Caris Life Sciences), Paradigm Diagnostics (acquired by Exact Sciences), Viomics (acquired by Exact Sciences), and the International Genomics Consortium (non-profit supported by the National Cancer Institute)..

Cirrus Bio开发并将多组学解决方案推向市场，用于疾病的诊断和管理，其中早期检测在临床结果中起着至关重要的作用。Cirrus Bio的创始人David Mallery（CEO）和Scott Morris（CSO）之前成立并领导了分子分析研究所（由Caris Life Sciences收购），Paradigm Diagnostics（由Exact Sciences收购），Viomics（由Exact Sciences收购）和国际基因组学联盟（由国家癌症研究所支持的非营利组织）。。

As part of the acquisition, Maverix also announced the formation of a dedicated diagnostic division called Maverix Dx that will develop, invest in, acquire, and bring to market a suite of diagnostic tools for lung cancer. David Mallery will serve as the Chief Executive Officer of Maverix Dx and Scott Morris as the Chief Scientific Officer.

作为收购的一部分，Maverix还宣布成立一个名为Maverix Dx的专门诊断部门，该部门将开发、投资、收购并将一套肺癌诊断工具推向市场。David Mallery将担任Maverix Dx的首席执行官，ScottMorris将担任首席科学官。

In these roles, they will continue to develop new diagnostic technologies, while also driving platform M&A and strategic investments..

在这些岗位上，他们将继续开发新的诊断技术，同时推动平台并购和战略投资。。

'Lung cancer remains the largest cancer killer, by far. The only way to improve survival rates for this extremely aggressive disease is to catch it early and act decisively. This acquisition gives Maverix unparalleled technology, talent, and expertise in early cancer detection, and will serve as the foundation for a broader diagnostic portfolio with the potential to transform lung cancer care,' said Duke Rohlen, Executive Chairman, Maverix Medical..

“到目前为止，肺癌仍然是最大的癌症杀手。提高这种极端侵袭性疾病存活率的唯一方法是尽早发现并果断行动。Maverix Medical执行董事长杜克·罗伦（DukeRohlen）说，此次收购为Maverix提供了无与伦比的早期癌症检测技术、人才和专业知识，并将为更广泛的诊断组合奠定基础，有可能改变肺癌护理。。

Cirrus represents the second major new product platform for Maverix. The first—Serpex Medical, announced at closing—has developed and obtained 510k clearance for steerable technologies that can precisely target lung tissue for biopsy or therapy delivery. Serpex will continue to serve as the foundation for the medical device division of Maverix, called Maverix Med Device, led by Serpex founder and CEO Sasha Schrode.

Cirrus代表了Maverix的第二个主要新产品平台。在闭幕式上宣布的第一个Serpex Medical已经开发并获得了510k的可操纵技术许可，可以精确靶向肺组织进行活检或治疗。Serpex将继续作为Maverix医疗器械部门的基金会，该部门名为Maverix Med device，由Serpex创始人兼首席执行官Sasha Schrode领导。

Together, Maverix Dx and Maverix Med Device will equip clinicians with the full range of diagnostic and interventional tools required for effective lung cancer treatment..

Maverix Dx和Maverix Med Device将共同为临床医生提供有效肺癌治疗所需的全套诊断和介入工具。。

'As we evaluate the lung cancer market, we see tremendous unmet clinical need and a rich opportunity set for both internal development and acquisitions. We are far from the only ones working on this tough clinical problem, and we look forward to partnering with other innovators to discover and validate new techniques for improving lung cancer care,' said David Mallery, CEO, Maverix Dx..

“在我们评估肺癌市场时，我们看到了巨大的未满足的临床需求，以及内部开发和收购的丰富机会。Maverix Dx首席执行官大卫·马利（DavidMallery）说：“我们远非唯一一家致力于解决这一棘手临床问题的公司，我们期待着与其他创新者合作，发现并验证改善肺癌护理的新技术。”。。

With the support of its financial sponsors and advisors, KKR and Hologic, Maverix Medical continues to invest in both development- and commercial-stage lung cancer companies and welcomes opportunities to collaborate with innovators, entrepreneurs, clinicians, and industry leaders.

在其财务赞助商和顾问KKR和Hologic的支持下，Maverix Medical继续投资于发展阶段和商业阶段的肺癌公司，并欢迎有机会与创新者、企业家、临床医生和行业领袖合作。

Contact:

联系人：

Diagnostic Inquiries – David Mallery, CEO, Maverix DX - dmallery@maverixmedical.com

诊断咨询–David Mallery，Maverix DX首席执行官dmallery@maverixmedical.com

Medical Device Inquiries – Sasha Schrode, CEO, Maverix Med Device - sschrode@maverixmedical.com

医疗器械查询–Sasha Schrode，Maverix Med Device首席执行官sschrode@maverixmedical.com

SOURCE Maverix Medical

来源Maverix Medical